Cargando…

The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells

Bortezomib is a novel anti-cancer agent which has shown promising activity in non-small lung cancer (NSCLC) patients. However, only a subset of patients respond to this treatment. We show that NSCLC cell lines are differentially sensitive to bortezomib, IC(50 )values ranging from 5 to 83 nM. The apo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voortman, Jens, Chęcińska, Agnieszka, Giaccone, Giuseppe
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194734/ https://www.ncbi.nlm.nih.gov/pubmed/18021420 http://dx.doi.org/10.1186/1476-4598-6-73

Ejemplares similares

Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report
por: Voortman, Jens, et al.
Publicado: (2006)

Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling
por: Voortman, Johannes, et al.
Publicado: (2009)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells
por: Checinska, Agnieszka, et al.
Publicado: (2006)

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
por: Taromi, Sanaz, et al.
Publicado: (2017)

Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
por: Cerruti, Fulvia, et al.
Publicado: (2017)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

TRIM28 attenuates Bortezomib sensitivity of hepatocellular carcinoma cells through enhanced proteasome expression
por: Zhang, Jianchao, et al.
Publicado: (2022)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells
por: Hattori, Kazuhiro, et al.
Publicado: (2021)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Elemene sensitizes pancreatic cancer cells to bortezomib by enhancing proteasome inhibition via molecular patch mechanism
por: Hou, Shurong, et al.
Publicado: (2023)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
por: Borjan, Bojana, et al.
Publicado: (2020)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma
por: Walter, Robert Fred Henry, et al.
Publicado: (2019)

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
por: Ferrer, Irene, et al.
Publicado: (2018)

MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer
por: Lee, Jih-Hsiang, et al.
Publicado: (2011)

Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial
por: Astakhova, Tatiana M., et al.
Publicado: (2018)

ATRT-01. UPREGULATION OF PROTEIN SYNTHESIS AND PROTEASOME DEGRADATION CONFERS SENSITIVITY TO PROTEASOME INHIBITOR BORTEZOMIB IN MYC-ATYPICAL TERATOID/RHABDOID TUMORS
por: Tran, Minh-Huy, et al.
Publicado: (2020)

Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines
por: de Carvalho, Fabricio, et al.
Publicado: (2011)

The Ubiquitin-Proteasome System in Apoptosis and Apoptotic Cell Clearance
por: Yuan, Lei, et al.
Publicado: (2022)

Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity
por: Lee, Jin Hee, et al.
Publicado: (2018)

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
por: Alexander, Tobias, et al.
Publicado: (2015)

Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL(3)B
por: Reynolds, Jennifer M, et al.
Publicado: (2007)

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
por: Allmeroth, Kira, et al.
Publicado: (2020)

Droxinostat sensitizes human colon cancer cells to apoptotic cell death via induction of oxidative stress
por: Huang, Ying, et al.
Publicado: (2018)

Cytotoxic and Apoptotic Effects of Pinostilbene and Bortezomib Combination Treatment on Human Multiple Myeloma Cells
por: Staskiewicz, Anna, et al.
Publicado: (2023)

Proteasome inhibition by bortezomib: A left hook and a right punch
por: Roelofs, Jeroen
Publicado: (2015)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
por: Wu, Yi-Xin, et al.
Publicado: (2016)

Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
por: Lee, Min Seung, et al.
Publicado: (2021)

Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis
por: Li, Shi-Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vncv8rog3b3fp13s49v2mosfim